Haptoglobin 2 allele associates with unstable carotid plaque and major cardiovascular events

Atherosclerosis

Volumn 230, Issue 2, 2013, Pages 228-234

  Ijäs, Petra ^a,b   Saksi, Jani ^b   Soinne, Lauri ^a   Tuimala, Jarno ^c   Jauhiainen, Matti ^d   Jula, Antti ^d   Kähönen, Mika ^e   Kesäniemi, Y Antero ^f   Kovanen, Petri T ^g   Kaste, Markku ^a   Lindsberg, Perttu J ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c FINNISH RED CROSS BLOOD SERVICE   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f UNIVERSITY OF OULU   (Finland)

^g WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Carotid stenoses; Intraplaque hemorrhage; Myocardial infarction; Stroke

Indexed keywords

HAPTOGLOBIN; HAPTOGLOBIN 2; HEME OXYGENASE 1; HEMOGLOBIN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY PLAQUE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSIENT ISCHEMIC ATTACK;

CAROTID STENOSES; INTRAPLAQUE HEMORRHAGE; MYOCARDIAL INFARCTION; STROKE;

AGED; ALLELES; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID STENOSIS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ENDARTERECTOMY, CAROTID; FEMALE; GENOTYPE; HAPTOGLOBINS; HEME OXYGENASE-1; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; POLYMORPHISM, GENETIC; RISK; STROKE;

EID: 84884572414     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.07.008     Document Type: Article

References (36)

1. Michel J., Virmani R., Arbustini E., Pasterkamp G. Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur Heart J 2011, 32:1977-1985.
2. Kristiansen M., Graversen J.H., Jacobsen C., Sonne O., Hoffman H.J., Law S.K., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409:198-201.
3. Langlois M.R., Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996, 42:1589-1600.
4. Nielsen M.J., Moestrup S.K. Receptor targeting of hemoglobin mediated by the haptoglobins: roles beyond heme scavenging. Blood 2009, 114:764-771.
5. Watanabe J., Chou K.J., Liao J.C., Miao Y., Meng H., Ge H., et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. JBiol Chem 2007, 282:23698-23707.
6. Guthrie P.A., Rodriguez S., Gaunt T.R., Lawlor D.A., Smith G.D., Day I.N. Complexity of a complex trait locus: HP, HPR, haemoglobin and cholesterol. Gene 2012, 499:8-13.
7. Froguel P., Ndiaye N.C., Bonnefond A., Bouatia-Naji N., Dechaume A., Siest G., et al. Agenome-wide association study identifies rs2000999 as a strong genetic determinant of circulating haptoglobin levels. PLoS One 2012, 7:e32327.
8. Igl W., Johansson A., Wilson J.F., Wild S.H., Polasek O., Hayward C., et al. Modeling of environmental effects in genome-wide association studies identifies SLC2A2 and HP as novel loci influencing serum cholesterol levels. PLoS Genet 2010, 6:e1000798.
9. Shen X., Wang W., Wang L., Houde C., Wu W., Tudor M., et al. Identification of genes affecting apolipoprotein B secretion following siRNA-mediated gene knockdown in primary human hepatocytes. Atherosclerosis 2012, 222:154-157.
10. Levy A.P., Levy J.E., Kalet-Litman S., Miller-Lotan R., Levy N.S., Asaf R., et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol 2007, 27:134-140.
11. Ijas P., Nuotio K., Saksi J., Soinne L., Saimanen E., Karjalainen-Lindsberg M., et al. Microarray analysis reveals overexpression of CD163 and HO-1 in symptomatic carotid plaques. Arterioscler Thromb Vasc Biol 2007, 27:154-160.
12. Saksi J., Ijäs P., Nuotio K., Sonninen R., Soinne L., Salonen O., et al. Gene expression differences between stroke-associated and asymptomatic carotid plaques. JMol Med (Berl) 2011, 89:1015-1026.
13. Guetta J., Strauss M., Levy N.S., Fahoum L., Levy A.P. Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis 2007, 191:48-53.
14. Nakhoul F.M., Marsh S., Hochberg I., Leibu R., Miller B.P., Levy A.P. Haptoglobin genotype as a risk factor for diabetic retinopathy. JAMA 2000, 284:1244-1245.
15. Levy A.P., Roguin A., Hochberg I., Herer P., Marsh S., Nakhoul F.M., et al. Haptoglobin phenotype and vascular complications in patients with diabetes. NEngl J Med 2000, 343:969-970.
16. Roguin A., Hochberg I., Nikolsky E., Markiewicz W., Meisel S.R., Hir J., et al. Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 2001, 87:330-332.
17. Levy A.P., Hochberg I., Jablonski K., Resnick H.E., Lee E.T., Best L., et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. JAm Coll Cardiol 2002, 40:1984-1990.
18. Roguin A., Koch W., Kastrati A., Aronson D., Schomig A., Levy A.P. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 2003, 26:2628-2631.
19. Koch W., Latz W., Eichinger M., Roguin A., Levy A.P., Schomig A., et al. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 2002, 48:1377-1382.
20. Rodriguez S., Gaunt T.R., Day I.N.M. Hardy-weinberg equilibrium testing of biological ascertainment for mendelian randomization studies. Am J Epidemiol 2009, 169:505-514.
21. Staals J., Pieters B.M., Knottnerus I.L., Rouhl R.P., van Oostenbrugge R.J., Delanghe J.R., et al. Haptoglobin polymorphism and lacunar stroke. Curr Neurovasc Res 2008, 5:153-158.
22. Chapelle J.P., Albert A., Smeets J.P., Heusghem C., Kulbertus H.E. Effect of the haptoglobin phenotype on the size of a myocardial infarct. NEngl J Med 1982, 307:457-463.
23. De Bacquer D., De Backer G., Langlois M., Delanghe J., Kesteloot H., Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 2001, 157:161-166.
24. Levy A.P., Larson M.G., Corey D., Lotan R., Vita J.A., Benjamin E.J. Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort. Atherosclerosis 2004, 172:361-365.
25. Asleh R., Marsh S., Shilkrut M., Binah O., Guetta J., Lejbkowicz F., et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003, 92:1193-1200.
26. Kalet-Litman S., Moreno P.R., Levy A.P. The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis 2010, 209:28-31.
27. Moreno P.R., Purushothaman K.R., Purushothaman M., Muntner P., Levy N.S., Fuster V., et al. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. JAm Coll Cardiol 2008, 52:1049-1051.
28. Lioupis C., Barbatis C., Drougou A., Koliaraki V., Mamalaki A., Klonaris C., et al. Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques. Atherosclerosis 2011, 216:131-138.
29. Watanabe J., Grijalva V., Hama S., Barbour K., Berger F.G., Navab M., et al. Hemoglobin and its scavenger protein haptoglobin associate with ApoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. JBiol Chem 2009, 284:18292-18301.
30. Asleh R., Miller-Lotan R., Aviram M., Hayek T., Yulish M., Levy J.E., et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes invitro and invivo. Circ Res 2006, 99:1419-1425.
31. Philippidis P., Mason J.C., Evans B.J., Nadra I., Taylor K.M., Haskard D.O., et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses invitro, in resolving skin blisters invivo, and after cardiopulmonary bypass surgery. Circ Res 2004, 94:119-126.
32. Milman U., Blum S., Shapira C., Aronson D., Miller-Lotan R., Anbinder Y., et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler Thromb Vasc Biol 2008, 28:341-347.
33. Farbstein D., Blum S., Pollak M., Asaf R., Viener H.L., Lache O., et al. Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype. Atherosclerosis 2011, 219:240-244.
34. Wilson S.H., Herrmann J., Lerman L.O., Holmes D.R., Napoli C., Ritman E.L., et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002, 105:415-418.
35. Derksen W.J.M., Peeters W., Tersteeg C., de Vries J.P.M., de Kleijn D.P.V., Moll F.L., et al. Age and coumarin-type anticoagulation are associated with the occurrence of intraplaque hemorrhage, while statins are associated less with intraplaque hemorrhage: a large histopathological study in carotid and femoral plaques. Atherosclerosis 2011, 214:139-143.
36. Doyle B., Caplice N. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. JAm Coll Cardiol 2007, 49:2073-2080.